Analyst Price Target is $10.50
▲ +6.82% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Apollo Endosurgery in the last 3 months. The average price target is $10.50, with a high forecast of $12.00 and a low forecast of $10.00. The average price target represents a 6.82% upside from the last price of $9.83.
Current Consensus is
The current consensus among 3 polled investment analysts is to hold stock in Apollo Endosurgery. This rating has held steady since December 2021, when it changed from a Buy consensus rating.
Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.